Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation
Listen to this summary
The authors aimed to investigate the association between apolipoprotein L1 gene (APOL1) polymorphisms and kidney function outcomes following living kidney donation. Their findings indicate that Black kidney donors with high-risk APOL1 genotypes are at a significantly increased risk of developing reduced kidney function post-donation, suggesting that APOL1 genotyping should be considered for Black living donor candidates to improve risk assessment.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from JAMA internal medicine
View all →Jun 22, 2026 · JAMA internal medicine
Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet Therapy
Jun 15, 2026 · JAMA internal medicine
2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans
Jun 15, 2026 · JAMA internal medicine
Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults
Jun 8, 2026 · JAMA internal medicine
Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical Trial
Jun 8, 2026 · JAMA internal medicine
Rehospitalization and the Association of Postoperative Delirium With Cognitive Decline in Older Adults
Jun 1, 2026 · JAMA internal medicine
Evaluating the Consequences of a Hypertension Management Incentive
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
